Noranelle

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Noranelle

Quick Facts

Property Description
Active Ingredients Ethinyl Estradiol, Levonorgestrel
Form Oral Tablet (Film-Coated)
Pharmacological Class Combined Hormonal Contraceptive (CHC)
Common Use Prevention of Pregnancy
Origin Synthetic (Estrogen and Progestin)

Noranelle: Defined as a Combined Hormonal Contraceptive

Noranelle is a specific prescription-only medication brand that belongs to the Combined Hormonal Contraceptive (CHC) pharmacological class, designated for the prevention of pregnancy in females of reproductive potential. This product is an established form of oral contraception that utilizes two distinct hormonal agents. Unlike progestin-only pills, this CHC formulation is designed to suppress the reproductive cycle via a dual hormonal approach. This class of medication is a standard contraceptive option used by women who seek reliable, systemic control over their fertility.

Composition: Ethinyl Estradiol, Levonorgestrel, and Drug Form

The active agents in Noranelle are the generic compounds Ethinyl Estradiol (an estrogen component) and Levonorgestrel (a progestin component), both of which are synthetic steroids. The medication is a combination product presented as a small, film-coated oral tablet intended for the oral route of administration. The fixed combination of these ingredients places Noranelle within a group of highly similar formulations, such as Lessina and Aviane. As with most oral contraceptives, the packaging includes both active tablets containing the hormones and inactive tablets (placebo), which are included for cycle management continuity.

How Noranelle Establishes Contraceptive Action

Noranelle establishes its contraceptive effect through coordinated physiological actions that fundamentally result in the prevention of pregnancy. The primary mechanism is the inhibition of ovulation, meaning the medication suppresses the signals that trigger the monthly release of an egg from the ovaries. Furthermore, the synthetic hormones alter the body’s environment by thickening the cervical mucus, thereby obstructing sperm entry into the uterus, and modifying the uterine lining to discourage potential implantation, providing a comprehensive, systemic approach to contraception.

Regulatory References

  1. NIH/NCBI Review on Combined Oral Contraceptive Pills

What side effects are possible with Noranelle?

Noranelle: Possible Side Effects and Safety Information

Noranelle (Ethinyl Estradiol and Levonorgestrel) is a combined hormonal contraceptive, and its safety profile is formally documented by regulatory agencies, classifying potential effects by frequency and the body system affected. These classifications are derived from clinical trial data and post-marketing surveillance.


Frequency-Classified Adverse Reactions

The safety profile is structured to identify common, expected effects. Very common adverse reactions (occurring in ge 10% of some trials) include headache, nausea, and irregular uterine bleeding (breakthrough bleeding or spotting). Effects officially categorized as common (occurring in ge 1% to <10%) include migraine, weight increase, mood changes, abdominal pain, acne, and breast tenderness.


Serious Adverse Reactions and Key Safety Considerations

The most significant, label-documented risk is the rare occurrence of thromboembolic events (blood clots), classified under Vascular Disorders. These serious adverse reactions include Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Stroke (Cerebrovascular Event), and Myocardial Infarction.

Regulatory documents explicitly state that the risk of these serious vascular events is heightened by factors such as smoking and being over 35 years of age. Furthermore, the risk of blood clots is highest during the first year of use and when restarting the medication after a break of four weeks or longer.

Common effects like irregular bleeding are noted as more likely during the initial months of treatment (first few cycles). A crucial safety restriction is that Noranelle does not protect against HIV infection (AIDS) or other sexually transmitted infections (STIs).

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for combined hormonal contraceptives like Noranelle provides a specific profile for acute overdosage. These statements are grounded in data concerning the acute ingestion of doses exceeding those prescribed, and they define the conditions under which emergency medical attention must be sought.

Documented Overdose Manifestations

Classification Regulatory Statement
Acute Symptoms Manifestations may include nausea, vomiting, and breast tenderness
Population Specific Withdrawal bleeding may occur in females, a temporary, documented acute effect.
Severity Status Serious ill effects have not been reported following the acute ingestion of large doses, including by young children.

Official Emergency Action

In the event that an overdosage is suspected, the officially mandated action is to contact a health-care provider or pharmacist for guidance. Overdosage is typically managed with entirely symptomatic and supportive treatment, as no specific pharmacological antidote is known to exist for this combination product. Urgent medical attention is required only for the presence of severe, life-threatening symptoms, which are not listed as the typical acute presentation of this overdosage.

Therapeutic Uses of Noranelle

What Noranelle Treats: Main Uses and Benefits

The combined hormonal formulation of Noranelle is commonly used across several therapeutic domains, primarily addressing the need for reliable pregnancy prevention while also providing supportive relief for managing menstrual and hormonal symptoms. This primary use contributes to easing the overall burden of fertility concerns.

This medication is applied in addressing conditions characterized by menstrual distress, helping to manage symptom clusters that may become intense or disruptive. It is commonly used to help with symptoms related to menstrual pain (dysmenorrhea), heavy menstrual blood loss (menorrhagia), and irregular cycle patterns. It is also considered relevant in clinical settings involving androgen-related skin symptoms, primarily acne vulgaris. This approach assists with maintaining functional stability and control over reproductive life, and contributes to improved comfort during symptomatic periods.

“The primary focus of use is fertility management, and the benefit in stabilizing the menstrual cycle supports daily functional comfort.”


Quick Fact: Relief for Key Symptom Clusters
Primary Use Focus Systemic, reliable prevention of pregnancy in reproductive-age females.
Menstrual Symptom Relief Easing pain related to cramping and assisting with heavy blood flow.
Hormonal Symptom Benefit Supporting management of persistent, androgen-related acne vulgaris.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The official regulatory criteria for Noranelle, a Combined Hormonal Contraceptive, define eligibility based on specific health conditions and age-related risk factors.

Populations for Whom Use is Contraindicated

Noranelle must not be used by patients with the following conditions, as stated in regulatory prescribing information:

  • Cigarette smokers aged 35 years or older.
  • Current or history of arterial or venous thrombotic diseases (e.g., deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction).
  • Known hypercoagulopathies or uncontrolled hypertension.
  • Known or suspected breast cancer or severe hepatic disease (e.g., liver tumors).
  • Diabetes mellitus complicated by vascular disease or other end-organ damage.
  • Migraine with focal neurological symptoms or any migraine in women over age 35.
  • Known or suspected pregnancy or undiagnosed abnormal uterine bleeding.

Age-Related Eligibility and Restrictions

Age Group Regulatory Status
Children (Pre-Menarche) Contraindicated for use before the onset of menstruation.
Geriatric (Postmenopausal) Not indicated for use in this population.
Lactation/Breastfeeding Not recommended due to the potential to affect milk supply and hormone transfer.

Use is restricted in the immediate postpartum period; initiation should not occur earlier than four weeks after delivery for non-breastfeeding women. The medication must also be discontinued at least four weeks before and through two weeks after major surgery involving prolonged immobilization.

What should I know about interactions with other medicines?

Official Interaction Map for Noranelle

Category Key Regulatory Summary
Contraindicated Combinations The product is formally contraindicated with Hepatitis C drug regimens containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir.
Exposure-Reducing Interactions Use with known CYP3A4 inducers, such as certain anticonvulsants (e.g., phenytoin, carbamazepine) and antibacterials (e.g., rifampin), is documented to decrease the plasma concentrations of the hormonal components. The herbal product St. John's Wort is also documented to reduce exposure via enzyme induction.
Exposure-Increasing Interactions The estrogen component is documented to increase the systemic exposure of drugs metabolized by CYP1A2, such as Tizanidine. The estrogen also raises binding globulin levels, which may increase the required dose of co-administered thyroid or corticosteroid replacement hormones. Certain substances, including Ascorbic Acid and Acetaminophen, are documented to potentially increase the Ethinyl Estradiol component's plasma concentration.
Population/Condition Notes Conditions causing severe or persistent diarrhea or vomiting are noted to temporarily decrease the absorption of the hormonal components.

Connection to the overall interaction profile:

The regulatory documentation defines Noranelle’s interaction structure primarily through its involvement in hepatic enzyme systems, leading to explicit contraindications and mandated classifications for exposure changes. The profile identifies numerous medicinal products and substances, including prescription drugs and herbal products, that officially alter the systemic exposure of either Noranelle's components or co-administered drugs. This information serves as the regulatory constraint for managing combination therapy to mitigate risks associated with reduced contraceptive efficacy or elevated plasma levels of other medications.

Mechanism of Action

How Noranelle Works

Noranelle functions as a selective antagonist of the receptor activator of nuclear factor kappa-B ligand ( RANKL). The drug is a recombinant analog of Osteoprotegerin ( OPG) designed to bind RANKL with high affinity. This binding event prevents the essential interaction between RANKL and its primary cellular receptor, RANK, which is situated on the surfaces of pre-osteoclasts and mature osteoclasts.

By inhibiting this specific RANKL signaling cascade, Noranelle suppresses the differentiation, activation, and survival of osteoclasts. This action decreases osteoclast-mediated bone resorption, thereby modulating the equilibrium between bone formation and bone resorption and resulting in a reduction of the overall rate of bone resorption.

Dosage and Administration Information

Noranelle is an oral tablet that is administered by mouth. The standard regimen requires taking one tablet daily on a continuous, repeating cycle. To ensure consistent systemic delivery, the tablet must be ingested at approximately the same time every day, ensuring the interval does not exceed 24 hours. The medication may be taken without regard to meals.

Official Dosing Protocol

The regimen is structured around a typical 28-day schedule that requires the sequential use of both active (hormone-containing) tablets and inactive (placebo) tablets, as indicated on the blister packaging. Administration must follow the exact numerical or sequential order provided for the specific pack configuration. For initial use, the protocols are the Day 1 Start (first day of menses) or the Sunday Start (first Sunday after menses starts).

Procedural Administration Rules

Procedural rules govern initiation and timing: when starting the regimen later than Day 1 of the menstrual cycle, an additional non-hormonal contraceptive method must be used for the first seven consecutive days of active tablet taking. The medication is used for long-term duration across repetitive cycles for as long as its use is desired. Dosage is uniform for post-menarchal females of reproductive age and is not indicated for postmenopausal use. Severe gastrointestinal disturbance within 3–4 hours of taking an active tablet requires following the specific instructions for a missed dose.

Recent Clinical Evidence

Evidence for Use in Preventing Pregnancy

The combined hormonal contraceptive formulation was evaluated in research for its application in pregnancy risk management. Research primarily involves large-scale Randomized Controlled Trials (RCTs) where studies monitored the rate of pregnancy, using the Pearl Index, over one year. The research examined groups of healthy women of reproductive age. Data show patterns related to outcomes measured in these studies. Subgroup findings are uncertain for women with a high Body Mass Index (BMI 30 kg/m^2 or higher) because results apply only to the populations studied in the main trials.


Evidence for Menstrual and Hormonal Symptom Management

The hormonal contraceptive class was evaluated in research exploring how symptoms change over time in conditions such as menstrual pain (dysmenorrhea), heavy menstrual bleeding (menorrhagia), and acne vulgaris. Studies monitored patient-reported outcomes describing perceived discomfort, blood loss, and changes in objective measures like acne lesion counts. Evidence from the broader class contributes to understanding how symptoms are measured. Comparative evidence is lacking to definitively characterize whether the specific dose of hormones in Noranelle can be associated with different outcomes compared to other similar preparations.


⏳ Study Limitations and Research Gaps

For its primary application, follow-up durations were limited in the main clinical trials, typically lasting for one year. For secondary uses, follow-up was often limited to intermediate-term periods, such as six months. This means that long-term effects are not fully established regarding the durability of symptom outcomes. There is limited information for long-term outcomes on the maintenance of results. Research provides context but not individual predictions, and study results reflect the specific conditions under which they were conducted.

Key Studies & References ACOG Practice Bulletin No. 206: Use of Hormonal Contraception in Women With Coexisting Medical Conditions

Frequently Asked Questions (FAQ)

Common questions about Noranelle (FAQ)


Q: Is Noranelle a type of antibiotic?

According to official product information, Noranelle is described as a Combined Hormonal Contraceptive (CHC). This means it is a medication containing synthetic hormones, and it is not classified as an antibiotic.


Q: Can Noranelle be used for conditions other than its main approved use?

The drug’s main use, as defined by regulatory documents, is the prevention of pregnancy. However, studies evaluating this class of medication have also examined its role in managing symptoms of conditions such as dysmenorrhea (menstrual pain) and acne vulgaris.


Q: Are there any long-term safety concerns associated with Noranelle?

Official documentation notes that serious adverse reactions, such as blood clots (thromboembolic events), are a documented risk, with the risk being noted as highest during the first year of use. Research also indicates that long-term safety findings are limited, as follow-up durations were restricted in the main clinical trials.


Q: How quickly does Noranelle start to work?

Official dosing protocols indicate that if the medication is started later than the first day of a woman's menstrual cycle, an additional non-hormonal method of contraception must be used for the first seven consecutive days. This procedural rule is designed to help establish the expected contraceptive effect, as outlined in the official protocols.


Q: Is it safe to drink alcohol while using Noranelle?

The formal regulatory documentation for this combination product does not explicitly mention an interaction with alcohol (ethanol). Regulatory documentation focuses on drug-drug interactions, and any questions about combining Noranelle with alcohol can be discussed with a healthcare provider.


Q: Can Noranelle be taken with over-the-counter pain relievers?

Regulatory documents state that certain substances, including Ascorbic Acid (Vitamin C) and the common pain reliever Acetaminophen, are documented to potentially increase the concentration of the estrogen component in the blood. This interaction is defined in the regulatory documentation for use in managing combination therapy.


Q: Are there any specific foods I should avoid while on Noranelle?

Official regulatory sources do not list specific food restrictions that must be avoided. However, some documentation mentions that grapefruit juice may increase the blood levels of the hormonal components by affecting the enzymes that process the drug.


Q: Is Noranelle suitable for teenagers?

Noranelle is indicated for use in post-menarchal females, meaning those who have already started menstruating. The medication is officially contraindicated for use before the onset of menstruation.


Q: Does Noranelle affect birth control pills?

Noranelle is itself a Combined Hormonal Contraceptive in the form of an oral tablet used to prevent pregnancy. Its official interaction profile describes documented effects with certain other medications, but not with other hormonal contraceptives.


Q: Can Noranelle make a person feel tired or drowsy?

The official safety profile, based on clinical trials for similar formulations, includes dizziness and fatigue among the documented adverse reactions reported by some patients. Information about all documented adverse reactions is available in the official prescribing information.


Q: Is Noranelle considered a controlled substance?

Official regulatory agencies, such as the DEA, have determined that Noranelle and other combined hormonal contraceptives are not classified as a controlled substance or drug due to a lack of recognized abuse or dependence potential.


Q: Is there a generic version of Noranelle available?

Noranelle is a brand-name medication. The active components it contains, Ethinyl Estradiol and Levonorgestrel, are available as generic versions of the combination formulation, as listed in regulatory drug compendiums.


Q: Does Noranelle change how my liver or kidneys work?

Official warnings note that the steroid hormones in the medication may be poorly metabolized in patients with impaired liver function. For this reason, use is contraindicated in patients who have severe liver disease or liver tumors.


Q: Can I take Noranelle if I have high blood pressure?

Noranelle is contraindicated (must not be used) in females with uncontrolled hypertension or hypertension that is complicated by vascular disease. For individuals with well-controlled hypertension, regulatory documents advise routine blood pressure monitoring.


Q: Can Noranelle affect my mood or mental state?

Mood changes and depression are classified as common adverse reactions based on clinical data. Regulatory documentation notes that women with a history of depression should be monitored by their healthcare provider.


Q: What happens if I stop taking Noranelle suddenly?

Official documentation does not describe the specific outcome of sudden cessation. However, the medication is prescribed for the long-term prevention of pregnancy, and discontinuation can be associated with a return of ovulation and changes in the menstrual bleeding pattern.


Q: What is the chemical makeup of Noranelle?

Noranelle is a combination product whose active agents are the generic compounds Ethinyl Estradiol and Levonorgestrel. These agents are formally described in regulatory documents as synthetic steroid hormones—an estrogen and a progestin.


Q: Does Noranelle have any known interaction with grapefruit juice?

Some regulatory sources indicate that consumption of grapefruit juice may increase the blood levels of the hormonal components of the medication. This could, in theory, affect how the body experiences the drug’s effects.


Q: Can Noranelle affect blood sugar levels?

Official documentation notes that the drug may decrease glucose tolerance. Regulatory documentation advises that prediabetic and diabetic women who take this medication are typically monitored for changes in blood sugar.


Q: Is it normal to feel a mild stomach upset when starting Noranelle?

Nausea is classified as a very common adverse reaction, and abdominal pain/cramps are classified as common adverse reactions in clinical trials. These effects are often most noticeable during the initial months of treatment.


Q: Does Noranelle have a risk of addiction or dependence?

Official regulatory bodies have not classified Noranelle as a controlled drug or substance, and dependence is not listed as a documented risk in the product information.


Q: Can I take Noranelle before driving?

Official product information does not contain explicit warnings about driving. However, common adverse reactions reported include dizziness and headache, which may potentially affect a person's ability to operate a vehicle.


Q: Does Noranelle cause problems with sleep?

The formal safety profile does not list specific sleep problems (such as insomnia) among the common or very common adverse reactions. However, other documented effects like mood changes could potentially affect sleep patterns.


Q: Is Noranelle available as a liquid or only as a pill?

Noranelle is officially presented as a small, film-coated oral tablet intended for the oral route of administration. Regulatory documentation does not list liquid or other physical forms of this product.

How should Noranelle be stored and disposed of?

Noranelle must be stored at Controlled Room Temperature, specifically between 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C (86 F). The medication must be protected from light and remain in its original container with the blister seal intact.

Child Safety and Disposal

The product must be kept out of the reach of children. For disposal of unused or expired tablets, regulatory guidelines emphasize using a drug take-back program or authorized disposal site if available. Do not flush Noranelle down the toilet. If a take-back program is unavailable, disposal may be done in household trash by mixing the tablets with an undesirable substance and sealing the mixture in a bag.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Noranelle found in:

A-Z Index: